FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Biosceptre announces today that Sir Gregory Winter, founder of Cambridge Antibody Technology, Domantis and a co-founder of Bicycle Therapeutics Limited has joined the Board as a non-executive Director. read more
Syncona LLP (“Syncona”), the evergreen healthcare investment company founded by the Wellcome Trust, announces today that its majority owned subsidiary, Blue Earth Diagnostics Ltd. (“BED”), a private diagnostics company, has received approval by the U.S. Food and Drug Administration (FDA) for a unique molecular imaging agent called Axumin™ (fluciclovine F 18) that identifies prostate cancer recurrence. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. read more
De eerste BioVox White Paper kijkt kritisch naar de uitdagingen en de opportuniteiten in de diagnosticasector. BioVox publiceert vandaag samen met Belgische experten uit de diagnosticawereld een rapport dat een kritisch inzicht geeft in de opportuniteiten en uitdagingen van een sector met duidelijk potentieel: het opsporen van ziektes staat sinds kort ook op de radar van Google en andere ICT-bedrijven. Binnen de gezondheidssector zelf, blijven de diagnosticabedrijven voorlopig ondergewaardeerd: diagnostica beïnvloeden meer dan 70% van de beslissingen, maar zien slechts 2% van het totale gezondheidsbudget hun richting uitkomen. Ook VC's houden hun portefeuille liever gesloten. read more
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the completion of the 21-day safety follow-up of the last patient enrolled in the third dose level cohort in its Phase I/IIa clinical trial evaluating the safety and feasibility of its NKR-2 T-cell therapy using T-cells with NKG2D receptor in Acute Myeloid Leukemia and Multiple Myeloma patients. No safety issues were reported. read more
Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that a post-hoc analysis of the worldwide Phase II TITAN study of its wholly-owned Nanobody®, caplacizumab, in patients with acquired thrombotic thrombocytopenic purpura (aTTP), will be presented at the 21st Congress of the European Hematology Association (EHA), being held from 9-12 June 2016 in Copenhagen, Denmark. read more
25 May 2016, 22.00 CET: Galapagos (Euronext & NASDAQ: GLPG) announces the presentation of detailed results from the Phase 2 FITZROY study of filgotinib in Crohn's Disease, at Digestive Disease Week (DDW) 2016 in San Diego, CA, USA, held from 21-24 May. read more
Multiplicom, leader in diagnostics for personalized medicine, has received a Flanders Innovation & Entrepreneurship R&D grant of €1.9 million ($2.1 million) to support the development of advanced technologies and targeted NGS-based tests to enable early diagnosis, treatment and monitoring of cancers. With this grant, Multiplicom will accelerate its development of liquid biopsy based NGS cancer tests that will improve the quality of life of cancer patients. read more
Galapagos NV (Euronext & NASDAQ: GLPG) reports the successful completion of the discussions with the regulatory authorities in the US and Europe and discloses the doses for the FINCH global Phase 3 program with filgotinib in RA. The FINCH program will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily, globally addressing a broad RA patient population, with dosing expected to begin in Q3'16. The FINCH Phase 3 program will also contain a dedicated male patient testicular safety study. read more
The Belgian companies ONTOFORCE and Tenacs Healthcare have teamed up to create InsightHealthcare – an innovatory platform which enables users to consult healthcare data in a new and efficient way. ONTOFORCE opened up its DISQOVER platform to Tenacs Healthcare, that was looking for the best way to share their wide range of data. read more
FlandersBio’s annual life sciences conference Knowledge for Growth is taking place for the 12th time in Ghent (Belgium) this year. A record number of 1,200 life science professionals from 470 companies & 16 different countries have registered, making Knowledge for Growth more and more a global impact conference. read more